Isolation and characterization of human multiple myeloma cell enriched populations

Journal of Immunological Methods

Volumn 235, Issue 1-2, 2000, Pages 11-19

  Tai, Yu Tzu ^a,b   Teoh, Gerrard ^a,b   Shima, Yoshihito ^a,b   Chauhan, Dharminder ^a,b   Treon, Steven P ^a,b   Raje, Noopur ^a,b   Hideshima, Teru ^a,b   Davies, Faith E ^a,b   Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dual fluorescence analysis; Enrichment methods; Immunomagnetic depletion; Multiple myeloma

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD32 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONONUCLEAR CELL; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; HUMANS; IMMUNOMAGNETIC SEPARATION; MULTIPLE MYELOMA; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 0033974904     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00199-4     Document Type: Article

References (28)

1. Anderson K.C., Lust J.A. Role of cytokines in multiple myeloma. Semin. Hematol. 36:1999;14-20.
2. Anderson K.C., Bates M.P., Slaughenhoupt B., Schlossman S.F., Nadler L.M. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J. Immunol. 132:1984;3172-3179.
3. Anderson K.C., Griffin J.D., Bates M.P., Slaughenhoupt B.L., Schlossman S.F., Nadler L.M. Isolation and characterization of human B lymphocyte enriched populations: I. Purification of B cells by immune rosette depletion. J. Immunol. Methods. 61:1983;283-292.
4. Anderson K.C., Hamblin T.J., Traynor A. Management of multiple myeloma today. Semin. Hematol. 36:1999;3-8.
5. Anderson K.C., Park E.K., Bates M.P., Leonard R.C., Hardy R., Schlossman S.F., Nadler L.M. Antigens on human plasma cells identified by monoclonal antibodies. J. Immunol. 130:1983;1132-1138.
6. Bakkus M.H., Van Riet I., Van Camp B., Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br. J. Haematol. 87:1994;68-74.
7. Borset M., Helseth E., Naume B., Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haematol. 85:1993;446-451.
8. Chauhan D., Bharti A., Raje N., Gustafson E., Pinkus G.S., Pinkus J.L., Teoh G., Hideshima T., Treon S.P., Fingeroth J.D., Anderson K.C. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 93:1999;1482-1486.
9. Ellis J.H., Barber K.A., Tutt A., Hale C., Lewis A.P., Glennie M.J., Stevenson G.T., Crowe J.S. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155:1995;925-937.
10. Fillola G., Muller C., Bousquet R., Fontanilles A.M., Laharrague P., Corberand J.X. Isolation of bone marrow plasma cells by negative selection with immunomagnetic beads. J. Immunol. Methods. 190:1996;127-131.
11. Funaro A., Spagnoli G.C., Ausiello C.M., Alessio M., Roggero S., Delia D., Zaccolo M., Malavasi F. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J. Immunol. 145:1990;2390-2396.
12. Goldmacher V.S., Bourret L.A., Levine B.A., Rasmussen R.A., Pourshadi M., Lambert J.M., Anderson K.C. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. 84:1994;3017-3025.
13. Goto T., Kennel S.J., Abe M., Takishita M., Kosaka M., Solomon A., Saito S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 84:1994;1922-1930.
14. Harada Y., Kawano M.M., Huang N., Mahmoud M.S., Lisukov I.A., Mihara K., Tsujimoto T., Kuramoto A. Identification of early plasma cells in peripheral blood and their clinical significance. Br. J. Haematol. 92:1996;184-191.
15. Huang N., Kawano M.M., Harada H., Harada Y., Sakai A., Kuramoto A., Niwa O. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood. 82:1993;3721-3729.
16. Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramoto A. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood. 73:1989;2145-2148.
17. Partington K.M., Jenkinson E.J., Anderson G. A novel method of cell separation based on dual parameter immunomagnetic cell selection. J. Immunol. Methods. 223:1999;195-205.
18. Portier M., Rajzbaum G., Zhang X.G., Attal M., Rusalen C., Wijdenes J., Mannoni P., Maraninchi D., Piechaczyk M., Bataille R.et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur. J. Immunol. 21:1991;1759-1762.
19. Rettig M.B., Ma H.J., Vescio R.A., Pold M., Schiller G., Belson D., Savage A., Nishikubo C., Wu C., Fraser J., Said J.W., Berenson J.R. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 276:1997;1851-1854.
20. Ribatti D., Vacca A., Nico B., Quondamatteo F., Ria R., Minischetti M., Marzullo A., Herken R., Roncali L., Dammacco F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer. 79:1999;451-455.
21. Stevenson F.K., Bell A.J., Cusack R., Hamblin T.J., Slade C.J., Spellerberg M.B., Stevenson G.T. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 77:1991;1071-1079.
22. Szczepek A.J., Seeberger K., Wizniak J., Mant M.J., Belch A.R., Pilarski L.M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 92:1998;2844-2855.
23. Tai Y.T., Strobel T., Kufe D., Cannistra S.A. In vivo cytotoxicity of ovarian cancer cells through tumor selective expression of the BAX gene. Cancer Res. 59:1999;2121-2126.
24. Teoh G., Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 11:1997;27-42.
25. Tong A.W., Lee J.C., Stone M.J. Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. Blood. 69:1987;238-245.
26. Van Riet I., Vanderkerken K., de Greef C., Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Med. Oncol. 15:1998;154-164.
27. Wijdenes J., Vooijs W.C., Clement C., Post J., Morard F., Vita N., Laurent P., Sun R.X., Klein B., Dore J.M. A plasmacyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 94:1996;318-323.
28. Yamamoto I., Kawano M., Sone T., Iwato K., Tanaka H., Ishikawa H., Kitamura N., Lee K., Shigeno C., Konishi J.et al. Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res. 49:1989;4242-4246.